Compare DexCom, Inc. (DXCM) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Hims and Hers Health Inc — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Hims and Hers Health Inc trades at $29.97 (market cap $7.12B). The key difference: DexCom, Inc. is far larger — about 4.7× Hims and Hers Health Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | HIMS | |
|---|---|---|
Market Cap | $33.79B | $7.12B |
Sector | Health | Health |
52-Week High | $89.53 | $62.76 |
52-Week Low | $54.84 | $14.52 |
Enterprise Value | $33.24B | $7.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
HIMS stock trades at $29.97, down 5.67% amid mixed Q2 2026 results. Revenue growth remains strong with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a net loss. Technical indicators are neutral to bearish, with support near $29. Recent news highlights an FTC investigation and class-action lawsuits adding uncertainty.
The outlook is cautious. Growth prospects from AI and global expansion are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33 price target, suggesting limited near-term upside amid execution and profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
